Abstract
Results of conventional chemotherapy for high-risk peripheral T-cell lymphoma (PTCL) are poor compared with those for their aggressive B-cell counterparts. We aim to review the current data on the use of hematopoietic SCT in these patients in both frontline and salvage settings. With respect to autologous SCT (ASCT), conclusions from retrospective studies are that ASCT in the salvage setting is as useful in PTCL as in aggressive B-cell lymphomas and also that consolidation in first complete response of high-risk patients has very good results when compared with conventional chemotherapy (with long-term PFS higher than 50%). From first frontline prospective clinical trials, it appears that ASCT is feasible and has a low TRM (<5%); consolidation in first complete response is associated with a very good outcome; around 25% of patients do not undergo ASCT due mainly to disease progression; new approaches aimed at increasing the number of chemosensitive patients should be found. Furthermore, 25–30% of patients deemed complete responders post transplant still relapse afterward. For all these mainly chemoresistant patients, there is preliminary evidence that allogeneic SCT (Allo-SCT) may produce a plateau in survival curves (with long-term PFS around 50%), which indicates a graft-versus-PTCL effect. For this reason, Allo-SCT procedures are the object of ongoing clinical trials.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Chan JK . Peripheral T-cell and NK-cell neoplasms: an integrated approach to diagnosis. Mod Pathol 1999; 12: 177–199.
A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89: 3909–3918.
Melnyk A, Rodriguez A, Pugh WC, Cabannillas F . Evaluation of the Revised European-American Lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma. Blood 1997; 89: 4514–4520.
Rüdiger T, Weisenburger DD, Anderson JR, Armitage JO, Diebold J, MacLennan KA et al. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 2002; 13: 140–149.
AbouYabis AN, Shenoy PJ, Flowers C, Lechowicz MJ . Response and survival rates in patients with peripheral T-cell lymphoma treated with anthracycline-based regimens: a comprehensive meta-analysis. Blood 2007; 110: 3452.
Savage KJ, Chhanabhai M, Gascoyne RD, Connors JM . Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol 2004; 15: 1467–1475.
Bierman P, Vose JM, Bociek RG, Loberiza F, Bast M, Weisenburger DD et al. Outcome of limited-stage peripheral T-cell lymphoma: results from the Nebraska Lymphoma Study Group. Blood 2007; 110: 3451.
Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM et al. ALK-negative anaplastic large-cell lymphoma (ALCL) is clinically and immunophenotypically different from both ALK-positive ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008; 111: 5496–5504.
Escalon MP, Liu NS, Yang Y, Hess M, Walker PL, Smith TL et al. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the MD Anderson Cancer Center experience. Cancer 2005; 103: 2091–2098.
Blystad AK, Enblad G, Kvaloy S, Berglund A, Delabie J, Holte H et al. High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas. Bone Marrow Transplant 2001; 27: 711–716.
Caballero MD, Perez-Simon JA, Iriondo A, Lahuerta JJ, Sierra J, Marin J et al. High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group. Ann Oncol 2003; 14: 140–151.
Kewalramani T, Zelenetz AD, Teruya-Feldstein J, Hamlin P, Yahalom J, Horwitz S et al. Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. Br J Haematol 2006; 134: 202–207.
Feyler S, Prince HM, Pearce R, Towlson K, Nivison-Smith I, Schey S et al. The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study. Bone Marrow Transplant 2007; 40: 443–450.
Rodriguez J, Conde E, Gutierrez A, Lahuerta JJ, Arranz R, Sureda A et al. The adjusted International Prognostic Index and beta-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma. Haematologica 2007; 92: 1067–1074.
Rodriguez J, Munsell M, Yazji S, Hagemeister FB, Younes A, Andersson B et al. Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol 2001; 19: 3766–3770.
Song KW, Mollee P, Keating A, Crump M . Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype. Br J Haematol 2003; 120: 978–985.
Jantunen E, Wiklund T, Juvonen E, Putkonen M, Lehtinen T, Kuittinen O et al. Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: a nation-wide survey. Bone Marrow Transplant 2004; 33: 405–410.
Smith SD, Bolwell BJ, Rybicki LA, Brown S, Dean R, Kalaycio M et al. Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen. Bone Marrow Transplant 2007; 40: 239–243.
Rodriguez J, Conde E, Gutierrez A, Arranz R, Leon A, Marin J et al. The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience. Ann Oncol 2007; 18: 652–657.
Rodriguez J, Caballero MD, Gutierrez A, Gandarillas M, Sierra J, Lopez-Guillermo A et al. High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience. Haematologica 2003; 88: 1372–1377.
Rodriguez J, Caballero MD, Gutierrez A, Marin J, Lahuerta JJ, Sureda A et al. High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience. Ann Oncol 2003; 14: 1768–1775.
Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 2004; 103: 2474–2479.
Rodriguez J, Conde E, Gutierrez A, Arranz R, Gandarillas M, Leon A et al. Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience. Eur J Haematol 2007; 78: 290–296.
Kyriakou C, Canals C, Goldstone A, Caballero D, Metzner B, Kobbe G et al. High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008; 26: 218–224.
Corradini P, Tarella C, Zallio F, Dodero A, Zanni M, Valagussa P et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 2006; 20: 1533–1538.
Reimer P, Ruediger T, Weissinger F, Mueller-Hermelink HK, Engert A, Einsele H et al. Different outcome for angioimmunoblastic T-cell lymphoma (AIL) and peripheral T-cell lymphoma unspecified (PTCL-U) following upfront autologous stem cell transplantation. Blood 2006; 108: 5431a.
d’Amore F, Relander T, Lauritzsen G, Jantunen E, Hagberg H, Anderson H et al. Dose-dense induction followed by autologous stem cell transplant (ASCT) as 1st line treatment in peripheral T-cell lymphomas (PTCL)—a Phase II Study of the Nordic Lymphoma Group (NLG). Blood 2006; 108: 401a.
Rodriguez J, Conde E, Gutierrez A, Arranz R, Leon A, Marin J et al. Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group. Eur J Haematol 2007; 79: 32–38.
Mercadal S, Briones J, Xicoy B, Pedro C, Escoda L, Estany C et al. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol 2008; 19: 958–963.
Reimer P, Schertlin T, Rüdiger T, Geissinger E, Roth S, Kunzmann V et al. Myeloablative radiochemotherapy followed by autologous peripheral blood stem cell transplantation as first-line therapy in peripheral T-cell lymphomas: first results of a prospective multicenter study. Hematol J 2004; 5: 304–311.
Reimer P, Rüdiger T, Einsele H, Geissinger E, Weissinger F, Nerl C et al. Autologous stem cell transplantation (autoSCT) as first-line therapy in peripheral T cell lymphomas (PTCL): results of a prospective multicenter study. J Clin Oncol 2008; 26: 8515.
Sureda A, Arranz R, Iriondo A, Carreras E, Lahuerta JJ, Garcia-Conde J et al. Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Gruppo Espanol de Linfomas/Transplante Autologo de Medula Osea Spanish Cooperative Group. J Clin Oncol 2001; 19: 1395–1404.
Mercadal S, Lopez-Guillermo A, Briones J, Xicoy B, Pedro C, Escoda L et al. Is there a role for autologous stem-cell transplantation (ASCT) in peripheral T-cell lymphoma (PTCL)? Final results of a prospective phase II study from the GELCAB. Blood 2006; 108: 3070a.
d’Amore F . High-dose therapy and autologous stem cell transplant as first line treatment in peripheral T-cell lymphomas. Ann Oncol 2005; 16: v15–v26.
Corradini P, Dodero A, Zallio F, Caracciolo D, Casini M, Bregni M et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 2004; 22: 2172–2176.
Le Gouill S, Milpied N, Buzyn A, De Latour RP, Vernant JP, Mohty M et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. J Clin Oncol 2008; 26: 2264–2271.
Wulf GG, Hasenkamp J, Jung W, Chapuy B, Truemper L, Glass B . Reduced intensity conditioning and allogeneic stem cell transplantation after salvage therapy integrating alemtuzumab for patients with relapsed peripheral T-cell non-Hodgkin's lymphoma. Bone Marrow Transplant 2005; 36: 271–273.
Tanosaki R, Kim S, Yamazaki S, Fukuda T, Mori S, Heike Y et al. A retrospective single institute analysis of 127 lymphoma patients who underwent allogeneic stem cell transplantation: impact on peripheral T-cell lymphoma (PTCL) including ATLL. Blood 2006; 108: 3031.
Zain J, Palmer J, Tsai N, Popplewell L, Nadamanee A, Krishnan A et al. Clinical outcomes of patients with T cell NHL undergoing allogeneic stem cell transplant. Blood 2006; 108: 3026.
O’Leary HM, Savage KJ, Toze CL, Connors JM, Gascoyne RD, Mourad YA et al. Allogeneic stem cell transplantation as treatment for relapsed and high-risk peripheral T-Cell lymphoma. Blood 2007; 110: 3040.
Günther A, Schade H, Humpe A, Gahn B, Claviez A, Schrauder A et al. BEAM-alemtuzumab followed by allogeneic SCT is a feasible and highly efficient treatment strategy in relapsed or refractory T-NHL. Bone Marrow Transplant 2008; 41 (S1): S244.
Hamadani M, Awan FT, Elder P, Lin TS, Porcu P, Blum KA et al. Allogeneic hematopoietic stem cell transplantation for peripheral T cell lymphomas: evidence of graft-versus-T cell lymphoma effect. Biol Blood Marrow Transplant 2008; 14: 480–483.
Kim JG, Sohn SK, Chae YS, Kim DH, Baek JH, Lee KB et al. CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas. Cancer Chemother Pharmacol 2006; 58: 35–39.
Kurzrock R, Ravandi F . Purine analogues in advanced T-cell lymphoid malignancies. Semin Hematol 2006; 43 (2 Suppl 2): S27–S34.
O’Connor OA, Hamlin PA, Portlock C, Moskowitz CH, Noy A, Straus DJ et al. Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma. Br J Haematol 2007; 139: 425–428.
Gallamini A, Zaja F, Patti C, Billio A, Specchia MR, Tucci A et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 2007; 110: 2316–2323.
Foss F . Clinical experience with denileukin diftitox (ONTAK). Semin Oncol 2006; 33 (1 Suppl 3): S11–S16.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gutiérrez, A., Caballero, M., Pérez-Manga, G. et al. Hematopoietic SCT for peripheral T-cell lymphoma. Bone Marrow Transplant 42, 773–781 (2008). https://doi.org/10.1038/bmt.2008.332
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2008.332
Keywords
This article is cited by
-
Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses
Journal of Hematology & Oncology (2014)
-
DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center
Annals of Hematology (2013)
-
Reduced-intensity allogeneic hematopoietic cell transplantation using fludarabine–melphalan conditioning for treatment of mature T-cell lymphomas
Bone Marrow Transplantation (2012)
-
Mature T-cell malignancies: a diagnostic and therapeutic challenge
memo - Magazine of European Medical Oncology (2009)